News Archives - Biomica

News

May 23, 2024

Biomica Presents Positive Clinical Data Update from Ongoing Phase 1 Trial of Microbiome-Based Therapeutic, BMC128, for Refractory RCC, NSCLC & Melanoma

Preliminary Phase 1 results show promising trends for BMC128 in combination with nivolumab in refractory cancer patients. Data will be showcased at the 2024 American Society of Clinical Oncology (ASCO) annual meeting REHOVOT, Israel, May 23, 2024. Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: […]

News

Apr 16, 2024

Biomica to Present at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

Biomica will present results from pre-clinical studies in its irritable bowel syndrome (IBS) program at the Digestive Disease Week (DDW) 2024 Annual Meeting. The conference is being held in Washington, D.C., May 18-21, 2024.

News

Apr 11, 2024

Biomica to Present at Digestive Disease Week (DDW) Conference 2024 Annual Meeting

News

Jan 23, 2024

Biomica CEO Set to Engage in Panel Discussion at 8th Annual European Microbiome Movement Summit

The summit gathers leading drug developers and microbiome experts to discuss microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up

News

Jan 17, 2024

Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug

The final patient completes Phase I trial enrollment, evaluating safety and tolerability for Biomica’s microbiome-based immuno-oncology drug, BMC128

News

Dec 21, 2023

Biomica CEO Set to Attend JP Morgan Healthcare Week in San Francisco, January 8-11, 2024

Dr. Elran Haber, CEO of Biomica, will be available for one-on-one meetings throughout the week, starting on Monday, January 8, and concluding on Thursday, January 11, 2024.

News

Aug 15, 2023

Biomica Opens Second Site to Advance Its Immuno-Oncology Drug Trials at Davidoff Center

Biomica Ltd. has announced the opening of a second site at The Davidoff Cancer Center for its ongoing Phase

News

Jul 19, 2023

Biomica Announces Interim Positive Results from Pre-Clinical Studies in its Irritable Bowel Syndrome (IBS) Program

The pre-clinical work was performed in collaboration with the lab of Prof. Kara Gross Margolis, Associate Director for Clinical and Translational Research for the New York University Pain Research Center and an Associate Professor in the Department of Molecular Pathobiology in the NYU College of Dentistry and the Department of Pediatrics at NYU Grossman School of Medicine.

News

Mar 14, 2023

Biomica VP R&D to Present at the Pharmabiotics 2023 Conference on March 21, 2023

Our VP R&D, Dr. Shiri Meshner, will be presenting at the Pharmabiotics 2023 Conference, “The Future of Microbiome-based Medicines”, taking place in Lyon, France from March 21-22, 2023.

News

Jan 24, 2023

Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome Movement

The results demonstrate the efficacy of Biomica’s live bacterial consortia, BMC426 and BMC427, for the treatment of IBS

12345❯

Newsroom